Mercy Medical Center, 301 St Paul Pl, Physician's Office Building, 7th Floor, Baltimore, MD, 21202, USA.
Sinai Hospital of Baltimore, Baltimore, MD, USA.
Dig Dis Sci. 2021 Jun;66(6):2000-2004. doi: 10.1007/s10620-020-06459-0. Epub 2020 Jul 11.
To compare the clinical outcomes of different protocols for fecal microbiota transplantation (FMT) in two community hospitals with similar patient demographics.
FMT is commonly performed for recurrent or refractory Clostridioides difficile infection (rCDI). The clinical efficacy of FMT for this indication has been well established. However, there has been no standardization or optimization of the amount of fecal material, method of feces preparation, or route of delivery for FMT.
In this retrospective study, patients with rCDI received FMT using commercially available frozen fecal preparation (22.7 g) at Center A and locally prepared fresh fecal filtrate (30-50 g) at Center B. The primary outcome was defined as complete resolution of clinical symptoms related to rCDI after at least 8 weeks of follow-up.
Fifty patients from each center were included in the study. Clinical success after initial FMT with lower-volume frozen fecal preparation at Center A was 32/50 (64.0%) compared to 49/50 (98.0%) with higher-volume fresh fecal filtrate at Center B (p < 0.0001). Seventeen patients in Center A and 1 patient in Center B underwent at least one repeat FMT. Overall clinical success was achieved in 43/50 (86%) of patients in Center A and 50/50 (100%) in Center B (p = 0.012).
Our results suggest superior clinical efficacy of a larger amount of fresh fecal filtrate over a smaller amount of commercially available frozen fecal preparation. Further studies are needed to examine the effect of varying amounts of feces and the optimal protocol for FMT in patients with rCDI.
比较两家社区医院在患者人群特征相似的情况下,采用不同方案进行粪便微生物群移植(FMT)的临床效果。
FMT 常用于治疗复发性或难治性艰难梭菌感染(rCDI)。该适应证下 FMT 的临床疗效已得到充分证实。但是,FMT 的粪便量、粪便准备方法或输送途径尚未标准化或优化。
在这项回顾性研究中,rCDI 患者在中心 A 接受市售冷冻粪便制剂(22.7g),在中心 B 接受本地制备的新鲜粪便滤液(30-50g)。主要结局定义为在至少 8 周的随访后,与 rCDI 相关的临床症状完全缓解。
每个中心各纳入 50 例患者。中心 A 采用小剂量冷冻粪便制剂初始 FMT 的临床成功率为 32/50(64.0%),而中心 B 采用大剂量新鲜粪便滤液的成功率为 49/50(98.0%)(p<0.0001)。中心 A 中有 17 例患者和中心 B 中有 1 例患者至少进行了一次重复 FMT。中心 A 中有 43/50(86%)的患者和中心 B 中有 50/50(100%)的患者总体临床成功率达到了(p=0.012)。
我们的结果表明,与小剂量市售冷冻粪便制剂相比,大量新鲜粪便滤液具有更好的临床疗效。需要进一步研究来检验不同粪便量和 rCDI 患者 FMT 最佳方案的效果。